Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients

Alemtuzumab, a humanized anti-CD52 monoclonal antibody, is approved for the treatment of highly active relapsing-remitting multiple sclerosis (MS). The principal adverse effect is the development of secondary autoimmune disorders during the immune reconstitution period after alemtuzumab, with autoim...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Main Authors: Kazakou, Paraskevi, Tzanetakos, Dimitrios, Vakrakou, Aigli G, Tzartos, John S, Anagnostouli, Maria, Koutsis, Georgios, Andreadou, Elisabeth, Evangelopoulos, Maria Eleptheria, Kilidireas, Constantinos, Zapanti, Evangelia
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2021
Assuntos:
Thyroid
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089514/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.1727
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares